Table 1.
Chronic administration of XJB-5–131 delays the onset of age-related functional decline in Ercc1-/Δ mice.
|
Age at onset (weeks) |
||||
|---|---|---|---|---|
| Symptom | Ercc1-/Δ+ vehicle | na | Ercc1-/Δ+ XJB-5–131 | nb |
| Dystonia | 7.4 | 8 | 8.6* | 10 |
| Trembling | 7.7 | 8 | 8.9 | 10 |
| Kyphosis | 11.7 | 8 | 13.2* | 10 |
| Ataxia | 14.5 | 8 | 16.3* | 10 |
| Hind-limb wasting | 14.0 | 8 | 16.0* | 10 |
| Reduced spontaneous activity | 17.5 | 5 | 20.9* | 5 |
| Urinary incontinence | 12.4 | 2 | n/a | 0 |
| Fraction of symptoms delayed | 10% | 8 | 66% | 8 |
a
Ercc1-/Δ mice + vehicle; n = 8 mice, 5 ♂; 2 ♀; n indicates the number of mice showing that symptom.
b
Ercc1-/Δ mice + XJB-5–131; n = 10 mice, 6 ♂; 4 ♀.
*
Individual symptoms that were significantly delayed in mice treated with XJB-5–131; p < 0.05 one-tailed Student’s t-test.